Hemostemix engages patentvest to strengthen its global patent portfolio

Calgary, alberta--(newsfile corp. - april 23, 2025) - hemostemix inc. (tsxv: hem) (otcqb: hmtxf) (fse: 2vf0) a leader in the development of autologous stem cell therapy for the treatment of cardiovascular diseases, announces its partnership with patentvest. patentvest, a subsidiary of mdb capital (nasdaq: mdbh), is a premier intellectual property strategy and patent prosecution firm specializing in life sciences.
MDBH Ratings Summary
MDBH Quant Ranking